This is not the most recent version of the article. View current version (13 MAR 2014)

Intervention Review

You have free access to this content

Vaccines for preventing influenza in healthy adults

  1. Vittorio Demicheli2,
  2. Carlo Di Pietrantonj3,
  3. Tom Jefferson4,
  4. Alessandro Rivetti3,
  5. Daniela Rivetti1,*

Editorial Group: Cochrane Acute Respiratory Infections Group

Published Online: 18 APR 2007

Assessed as up-to-date: 8 JAN 2006

DOI: 10.1002/14651858.CD001269.pub3


How to Cite

Demicheli V, Di Pietrantonj C, Jefferson T, Rivetti A, Rivetti D. Vaccines for preventing influenza in healthy adults. Cochrane Database of Systematic Reviews 2007, Issue 2. Art. No.: CD001269. DOI: 10.1002/14651858.CD001269.pub3.

Author Information

  1. 1

    Servizio di Igiene e Sanita' Pubblica, ASL 19 Asti, Public Health Department, Asti, Italy

  2. 2

    Regione Piemonte - Azienda Sanitaria Locale ASL AL, Health Councillorship - Servizio Regionale di Riferimento per l'Epidemiologia, SSEpi-SeREMI - Cochrane Vaccines Field, Torino, Piemonte, Italy

  3. 3

    Azienda Sanitaria Locale ASL AL, Servizio Regionale di Riferimento per l'Epidemiologia, SSEpi-SeREMI - Cochrane Vaccines Field, Alessandria, Piemonte, Italy

  4. 4

    The Cochrane Collaboration, Vaccines Field, Roma, Italy

*Daniela Rivetti, Public Health Department, Servizio di Igiene e Sanita' Pubblica, ASL 19 Asti, Via Conte Verde, 125, Asti, 14100, Italy. epidemiologia@asl.at.it.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 18 APR 2007

SEARCH

This is not the most recent version of the article. View current version (13 MAR 2014)

 

Background

  1. Top of page
  2. Background
  3. Objectives
  4. Methods
  5. Results
  6. Discussion
  7. Authors' conclusions
  8. Acknowledgements
  9. Data and analyses
  10. Appendices
  11. Feedback
  12. What's new
  13. History
  14. Contributions of authors
  15. Declarations of interest
  16. Sources of support
  17. Index terms

Viral respiratory disease imposes a heavy burden on society. The majority of viral respiratory disease (influenza-like illness) is caused by a many different agents, which are not clinically distinguishable from one another. A proportion of influenza-like illness is caused by influenza viruses and is known as influenza (Jefferson 2004).

Influenza is an acute respiratory infection caused by a virus of the Orthomyxoviridae family. Three serotypes are known (A, B and C). Influenza causes an acute febrile illness with myalgia, headache and cough. Although the median duration of the acute illness is three days, cough and malaise can persist for weeks. Complications of influenza include otitis media, pneumonia, secondary bacterial pneumonia, exacerbations of chronic respiratory disease and bronchiolitis in children. Additionally, influenza can cause a range of non-respiratory complications including febrile convulsions, Reye's syndrome and myocarditis (Wiselka 1994). Efforts to prevent or minimise impact of seasonal influenza in the second part of the 20th century have centred on the use of vaccines. Due to the yearly changes in viral antigenic configuration and the lack of carry-over protection from year to year, vaccination campaigns annually require a huge scientific and logistic effort to ensure production and delivery of that year's vaccines for high population coverage.

Current influenza vaccines are of three types: (1) whole virion vaccines which consist of complete viruses which have been "killed" or inactivated, so that they are not infectious but retain their strain-specific antigenic properties; (2) subunit virion vaccines which are made of surface antigens (H and N) only; (3) split virion vaccines in which the viral structure is broken up by a disrupting agent. These vaccines contain both surface and internal antigens. In addition a variety of non-European manufacturers produce live attenuated vaccines. Traditionally whole virion vaccines are thought to be the less well-tolerated because of the presence of a lipid stratum on the surface of the viral particles (a remnant of the host cell membrane coating the virion, when budding from the host cell). Influenza vaccines are produced worldwide. Periodic antigenic drifts and shifts pose problems for vaccine production and procurement, as a new vaccine closely matching circulating antigenic configuration must be produced and procured for the beginning of each new influenza 'season'. To achieve this, the World Health Organization (WHO) has established a worldwide surveillance system allowing identification and isolation of viral strains circulating the different parts of the globe. Sentinel practices recover viral particles from the naso-pharynx of patients with influenza-like symptoms and the samples are swiftly sent to the laboratories of the national influenza centres (110 laboratories in 79 countries). When new strains are detected the samples are sent to one of the four WHO reference centres (London, Atlanta, Tokyo and Melbourne) for antigenic analysis. Information on the circulating strain is then sent to the WHO, who in February of each year recommends, through a committee, the strains to be included in the vaccine for the forthcoming 'season'. Individual governments may or may not follow the WHO recommendations. Australia, New Zealand and more recently South Africa, follow their own recommendations for vaccine content. Surveillance and early identification thus play a central part in the composition of the vaccine.

Every vaccination campaign has stated aims against which the effects of the campaign must be measured. Perhaps the most detailed document presenting the rationale for a comprehensive preventive programme is that by the US Advisory Committee on Immunization Practices (ACIP) which is regularly updated (ACIP 2006). The current version identifies 11 categories at high risk of complications from influenza, among which are healthy adults aged 50 to 65 years of age and healthcare workers. The rationale for policy choices rests on the heavy burden which influenza imposes on the populations and on the benefits accruing from vaccinating them. Reductions in cases and complications (such as excess hospitalisations, absence from work, mortality and healthcare contacts) and the interruption of transmission, are the principal arguments for extending vaccination to healthy adults aged 50 to 65 years (ACIP 2006). Given the very high cost of yearly vaccination for large parts of the population and the extreme variability of influenza incidence during each "season", we carried out a systematic review of the evidence. To enhance relevance for decision-makers in the 2006 update of the review we included comparative non-randomised studies reporting evidence of serious and/or rare harms.

 

Objectives

  1. Top of page
  2. Background
  3. Objectives
  4. Methods
  5. Results
  6. Discussion
  7. Authors' conclusions
  8. Acknowledgements
  9. Data and analyses
  10. Appendices
  11. Feedback
  12. What's new
  13. History
  14. Contributions of authors
  15. Declarations of interest
  16. Sources of support
  17. Index terms

To identify, retrieve and assess all studies evaluating the effects (efficacy, effectiveness and harm) of vaccines against influenza in healthy adults we defined:

  1. efficacy as the capacity of the vaccines to prevent influenza A or B and its complications;
  2. effectiveness as the capacity of the vaccines to prevent influenza-like illness and its consequences;
  3. harm as any harmful event potentially associated with exposure to influenza vaccines.

 

Methods

  1. Top of page
  2. Background
  3. Objectives
  4. Methods
  5. Results
  6. Discussion
  7. Authors' conclusions
  8. Acknowledgements
  9. Data and analyses
  10. Appendices
  11. Feedback
  12. What's new
  13. History
  14. Contributions of authors
  15. Declarations of interest
  16. Sources of support
  17. Index terms
 

Criteria for considering studies for this review

 

Types of studies

Any randomised or quasi-randomised studies* comparing influenza vaccines in humans with placebo or no intervention or comparing types, doses or schedules of influenza vaccine. Only studies assessing protection from exposure to naturally occurring influenza were considered.

Comparative non-randomised studies were included if they reported evidence on the association between influenza vaccines and serious adverse effects (such as Guillain-Barré or oculo-respiratory syndromes).

*A study is randomised when it appears that the individuals (or other experimental units) followed in the study were definitely or possibly assigned prospectively to one of two (or more) alternative forms of health care using random allocation. A study is quasi-randomised when it appears that the individuals (or other experimental units) followed in the study were definitely or possibly assigned prospectively to one of two (or more) alternative forms of health care using some quasi-random method of allocation (such as alternation, by date of birth or by case record number).

 

Types of participants

Healthy individuals aged 16 to 65 years, irrespective of influenza immune status. Studies considering more than 25 percent of individuals outside this age range were excluded from the review.

 

Types of interventions

Live, attenuated or killed vaccines or fractions thereof administered by any route, irrespective of antigenic configuration.

 

Types of outcome measures

 

Clinical

Numbers and seriousness (complications and working days lost) of influenza and influenza-like illness cases occurring in vaccine and placebo groups.

 

Harms

Number and seriousness of adverse effects (classified as local, systemic and severe). Systemic adverse effects include cases of malaise, nausea, fever, arthralgia, rash, headache and more generalised and serious signs. Local adverse effects include induration, soreness and redness at the site of inoculation.

 

Search methods for identification of studies

For the previous (2004) update, we searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library, Issue 1, 2004) which contains the Cochrane Acute Respiratory Infections Group's trials register; MEDLINE (January 1966 to December 2003); and EMBASE (1990 to December 2003). There were no language restrictions.

See Appendix 1 for the MEDLINE search strategy used. This search strategy was modified and repeated in CENTRAL and EMBASE databases. There were no language restrictions. In order to identify further trials, we read the bibliography of retrieved articles and handsearched the journal Vaccine from its first issue to the end of 2003. Results of handsearches are included in CENTRAL. In order to locate unpublished trials, for the first edition of this review, we wrote to the following: manufacturers; first or corresponding authors of studies in the review.

For the present update, we searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library, Issue 4, 2005) which contains the Cochrane Acute Respiratory Infections Group's trials register; MEDLINE (January 1966 to January 2006); and EMBASE (1990 to January 2006) without language restrictions. The following search strategy was used for MEDLINE and the search terms were adapted for the other searched databases:

MEDLINE
#1 "Influenza Vaccines"[MeSH] OR ("Influenza, Human/complications"[MeSH] OR "Influenza, Human/epidemiology"[MeSH] OR "Influenza, Human/immunology"[MeSH] OR "Influenza, Human/mortality"[MeSH] OR "Influenza, Human/prevention and control"[MeSH] OR "Influenza, Human/transmission"[MeSH])
#2 (influenza vaccin*[Title/Abstract]) OR ((influenza [Title/Abstract] OR flu[Title/Abstract]) AND (vaccin*[Title/Abstract] OR immuni*[Title/Abstract] OR inoculation*[Title/Abstract] OR efficacy[Title/Abstract] OR effectiveness[Title/Abstract]))
#3 #1 OR #2
#4 (randomized controlled trial[Publication Type] OR controlled clinical trial[Publication Type] OR randomized controlled trials[MeSH Terms] OR random allocation[MeSH Terms] OR double-blind method[MeSH Terms] OR single-blind method[MeSH Terms] OR clinical trial[Publication Type] OR clinical trials[MeSH Terms]) OR ("clinical trial"[Text Word]) OR ((singl*[Text Word] OR doubl*[Text Word] OR trebl*[Text Word] OR tripl*[Text Word]) AND (mask*[Text Word] OR blind*[Text Word])) OR (placebos[MeSH Terms] OR placebo*[Text Word] OR random*[Text Word] OR research design [mh:noexp]) NOT (animals[MeSH Terms] NOT human[MeSH Terms])
#5 "Case-Control Studies"[MeSH] OR (cases[Title/Abstract] AND controls[Title/Abstract]) OR case control stud*[Title/Abstract]
#6 "Cohort Studies"[MeSH] OR cohort stud*[Title/Abstract]
#7 confidence interval[Title/Abstract] OR relative risk[Title/Abstract] OR CI[Title/Abstract] OR RR[Title/Abstract] OR epidemic[Title/Abstract]
#8 #4 OR #5 OR #6 OR #7
#9 #3 AND #8
#10 #3 AND #8 Field: All Fields, Limits: Adult: 19-64 years
#11 adult OR adults OR adulthood
#12 #8 AND #11
#13 #10 AND #12

 

Data collection and analysis

 

Inclusion procedure

Two review authors (TJ and DR) independently applied inclusion criteria to all identified and retrieved articles. Three review authors (TJ, DR and AR) extracted data from included studies on standard Cochrane Vaccines Field forms. The procedure was supervised and arbitrated by CDP. Assessment of methodological quality for RCTs was carried out using criteria from the Cochrane Reviewers' Handbook (Higgins 2005). We assessed studies according to randomisation, generation of the allocation sequence, allocation concealment, blinding and follow up. We assessed quality of non-randomised studies in relation to the presence of potential confounders using the appropriate Newcastle-Ottawa Scales (Wells 2004). We used quality at the analysis stage as a means of interpretation of the results. We assigned risk of bias categories on the basis of the number of NOS items judged inadequate in each study: low risk of bias - up to 1 inadequate item; medium risk of bias - up to 3 inadequate items; high risk of bias - more than 3 inadequate items; very high risk of bias - when there was no description of methods.

 

Data synthesis

The tables of comparisons were constructed according to the following criteria.

  1. Inactivated parenteral (intramuscular or subcutaneous) influenza vaccines versus placebo or no intervention (Comparison 01).
  2. Live aerosol vaccines (Comparison 02).
  3. Inactivated aerosol vaccines (Comparison 03).

For all three major comparisons, subgroup analyses were carried out according to the degree of matching with that year's WHO recommended content and with circulating viruses ("WHO recommended and matching" when known). WHO recommendations on content of vaccines have been published since 1973. Different dosages and schedules of the vaccine and the presence of different adjuvants were not compared and data from arms of trials comparing only vaccine composition or dosage were pooled in the analysis. Compliance of the study vaccine with the official antigenic content and potency recommendations was checked by reviewing WHO records when possible. In case of uncertainty due to ambiguity of wording used (in the oldest trials), the opinion stated by authors was taken into account. The compliance of a live attenuated vaccine with the recommendation was classified according to the antigenic comparability of the wild strains.

The following outcomes were included in the comparisons.

  1. Cases of influenza (defined on the basis of a specific list of symptoms and/or signs backed up by laboratory confirmation of infection with influenza A or B viruses).
  2. cases of influenza-like illness (clinically defined on the basis of a specific list of symptoms and/or signs).
  3. hospital admissions.
  4. complications.
  5. working days lost.
  6. local harms.
  7. systemic harms.
  8. severe/rare harms.

The statistic I2 was calculated for each pooled estimate, in order to assess the impact on statistical heterogeneity . I2 may be interpreted as the proportion of total variation among effect estimates that is due to heterogeneity rather than sampling error, and it is intrinsically independent of the number of studies. When I2 < 30% there is little concern about statistical heterogeneity (Higgins 2002; Higgins 2003). We used random-effects models throughout to take account of the between-study variance in our findings (DerSimonian 1986). Variance is to be expected in influenza vaccine trials as there are unpredictable systematic differences between trials regarding the circulating strains, degree of antigenic matching of the vaccine, type of vaccine, and the levels of immunity presented by different population in different settings. Not all studies reported sufficient details to enable a full analysis of the sources of heterogeneity, but we were able to take into account vaccine matching and circulating strain. Efficacy (against influenza) and effectiveness (against ILI) (effects) estimates were summarised as relative risk (RR) within 95% confidence intervals (CI) (in brackets after the summary estimate). Absolute vaccine efficacy (VE) was expressed as a percentage using the formula: VE = 1-RR whenever statistically significant. We did not perform a quantitative analysis of non-randomised studies.

Similar analyses were undertaken for other events, such as complications, hospital admissions and harms.

As the data on average time off work was reported as a continuous measurement, these results were expressed as differences in means, and combined using the mean difference method. Caution should be exercised in interpreting these results as the data are very skewed. Several trials included more than one active vaccine arm. Where several active arms from the same trial were included in the same analysis, the placebo group was split equally between the different arms, so that the total number of subjects in any one analysis did not exceed the actual number in the trials. As it was not possible to identify all sources of heterogeneity, we decided to carry out a sensitivity analysis on the results applying fixed-effect and a random-effects models to assess the impact of heterogeneity on our results. Finally, because of the widespread concern about the possible impact of a future influenza pandemic we carried out a separate analysis of trials carried out during the 1968 to 1969 (H3N2) pandemic.

Four different definitions of "epidemic period" were found.

  1. The interval between the first and the last virus isolation in the community.
  2. the interval during which influenza virus was recovered from more than a stated percentage of ill subjects.
  3. the period during which an increase of respiratory illness more than a stated % was recorded.
  4. the winter period taken as a proxy for epidemic period.

The data were included regardless of the definition of epidemic period used in the primary study. When data were presented for the epidemic period and the entire follow up period, those which occurred during the former were considered.

An influenza-like illness case (specific definition) was assumed to be the same as a "flu-like illness" according to a predefined lists of symptoms (including the Centres for Disease Control (CDC) case definition for surveillance), or "upper respiratory illness" according to a predefined lists of symptoms. When more than one definition was given for the same trial, data related to the more specific definition were included.
The laboratory confirmation of influenza cases found were:

  1. virus isolation from culture;
  2. four-fold antibody increase (haemagglutinin) in acute or convalescent phase sera; and
  3. four-fold antibody increase (haemagglutinin) in post-vaccination or post-epidemic phase sera.

When more than one definition was given for the same trial, data related to the more sensitive definition (for example, influenza) were included.
Hospital admissions rates were calculated as proportion of cases hospitalised for respiratory causes. Complications were considered as proportion of cases complicated by bronchitis, pneumonia or otitis.
Working days lost in episodes of sickness absence regardless of cause were also considered. Only five trials used working days lost as an outcome measure and four of them measured the work absence in terms of difference of the average number of days lost in the two arms of the trial (Comparison 01 07). These studies presented a value of standard error measured accordingly. The remainder (Nichol 1999a) expressed the work absence in terms of rate ratio and this does not allow the recalculation of the correct estimate of the standard error. Therefore this study was excluded from the pooled analysis.

Local symptoms are presented separately from systemic symptoms. Individual harms have been considered in the analysis, as well as a combined endpoint (any or highest symptom). All the data included in the analysis were used as presented by the authors in the primary study regardless of the number of drop-outs. This approach (complete case scenario) was decided because the majority of the studies did not present any attempt at using an intention to treat analysis nor mentioned the reasons for the loss to follow up and did not contain detailed information to allow estimations of the real number of participants.

 

Results

  1. Top of page
  2. Background
  3. Objectives
  4. Methods
  5. Results
  6. Discussion
  7. Authors' conclusions
  8. Acknowledgements
  9. Data and analyses
  10. Appendices
  11. Feedback
  12. What's new
  13. History
  14. Contributions of authors
  15. Declarations of interest
  16. Sources of support
  17. Index terms
 

Description of studies

See: Characteristics of included studies; Characteristics of excluded studies.

The first version of the review contained 20 studies. The 2004 version added five more. In 2006 we included 48 studies in all. Some of them had more than two arms, comparing different vaccines, routes of administration, schedules or dosages and reported data from different settings and epidemic seasons. We split these studies into sub-studies (datasets). For the remaining of this review the word "study report" will identify the original study report while the wold "dataset" will identify the sub-study. Details of the division of the reports of studies into datasets are given in the table of included studies.
Overall, 25 datasets contributed data on efficacy/effectiveness (16 on inactivated parentereral vaccines, seven on live aerosol vaccines and two on inactivated aerosol vaccines), 12 on all effects (seven on inactivated parenteral vaccines, three on live aerosol vaccines and two on inactivated aerosol vaccines) and 20 on harms only (nine on inactivated parentereral vaccines, nine on live aerosol vaccines and two on inactivated aerosol vaccines) ( Table 1).

Included trials assessed three types of vaccine: inactivated parenteral, live attenuated aerosol and inactivated aerosol.

Thirty-two datasets of inactivated parenteral vaccine were included. Sixteen datasets (10 study reports) provided data about efficacy or effectiveness (Eddy 1970; Hammond 1978; Keitel 1988a; Keitel 1988b; Keitel 1997a; Keitel 1997b; Keitel 1997c; Leibovitz 1971; Mixéu 2002; Mogabgab 1970a; Mogabgab 1970b; Powers 1995b; Powers 1995c; Waldman 1969a; Waldman 1969b; Weingarten 1988). They involved 20,718 subjects, 9317 in the vaccines arm and 11,401 in the placebo arms.
Seven datasets (five study reports) reported both effectiveness and harms data (Bridges 2000a; Bridges 2000b; Mesa Duque 2001; Nichol 1995; Powers 1995a; Waldman 1972b; Waldman 1972d). The population sample of these consisted of 4227 people, 2251 received vaccine, and 1976 received placebo.
The remaining nine datasets (nine studies) with inactivated parentereral vaccines assessed harms outcomes only and were carried out on 2931 subjects (Caplan 1977; El'shina 1996; Forsyth 1967; Goodeve 1983; Phyroenen 1981; Rocchi 1979a; Saxen 1999; Scheifele 2003; Tannock 1984). In this last group, 1560 subjects were immunised, and 1371 received placebo.

Live aerosol vaccines were tested in 19 datasets.
Seven datasets (three studies) reported efficacy / effectiveness outcomes (Edwards 1994a; Edwards 1994b; Edwards 1994c; Edwards 1994d; Sumarokow 1971; Zhilova 1986a; Zhilova 1986b). Altogether 29,955 subjects were involved, 15,651 in vaccines and 14,304 in the placebo arms. Three datasets (three studies) provided effectiveness and harms data (Monto 1982; Nichol 1999a; Rytel 1977), 5010 individuals in all, 3290 in vaccines arms and 1720 in placebo. Nine datasets (eight studies) reported harms data only (Atmar 1990; Betts 1977a; Evans 1976; Hrabar 1977; Keitel 1993a; Keitel 1993b; Lauteria 1974; Miller 1977; Rocchi 1979b): 630 in the vaccinated and 344 in the placebo arms; 974 observations in total.

Six datasets with inactivated aerosol vaccine were included.
Two datasets provided data on efficacy or effectiveness only (Waldman 1969c; Waldman 1969d). The total number of subjects was 1187: with 950 who were vaccinated and 237 who received placebo.
Two datasets (one study) evaluated efficacy / effectiveness and harms (Waldman 1972a; Waldman 1972c) with a total population of 487: 389 in the vaccine arms 389 and 98 in the placebo arms.
Two trials (two studies) reported data on harms outcomes only (Boyce 2000; Langley 2005), with a total population of 151,120 in the vaccine arms and 31 in the placebo arms).

Two studies with live aerosol vaccine (Reeve 1982; Spencer 1977) each one data set) could not be introduced in the harms analysis (secondary effects) because data did not allow quantitative analysis (systemic and local harms were reported as given cumulative in Spencer 1977 and data were not clearly reported in Reeve 1982).

Ten studies (eight of which were comparative non-randomised studies) investigated possible associations between influenza vaccines and serious harms:
Atmar 1990 (respiratory function), DeStefano 2003 (multiple sclerosis and optic neuritis), Kaplan 1982 (Guillan Barrè Syndrome (GBS)), Lasky 1998 (GBS) Mastrangelo 2000 (Cutaneous Melanoma), Mutsch 2004 (Bell's palsy), Payne 2006 (optic neuritis), Scheifele 2003 (oculo respiratory syndrome), Shoenberger 1979 (GBS); Siscovick 2000 (Cardiac arrest).

Included studies are described in the relevant table.

 

Risk of bias in included studies

In the included trials, allocation concealment was adequate in 10, inadequate in four, unclear in 24 and not relevant in two. Assessment was double-blinded in 23 studies. Five studies were single blind and twelve did not mention blinding. Thirty-one studies were properly randomised, seven stated that the allocation method was quasi-random and two studies were field trials.

Three non randomised studies were at high risk of bias (Kaplan 1982; Mastrangelo 2000; Siscovick 2000), one was at medium risk of bias (Mutsch 2004) and two were at low risk of bias (Atmar 1990; Lasky 1998).

 

Effects of interventions

 

Inactivated parenteral vaccines (Comparison 01)

Inactivated parenteral vaccines were 30% effective (95% CI 27% to 41%) against influenza-like illness if content matched WHO recommendations and circulating strain, but this decreased to 12% (95% CI 28% to 0%) when these were unknown (Comparison 01 01). However, effectiveness was considerably lower (16%, 95% CI 9% to 23%) when the studies carried out during the 1968 to 1969 pandemic were excluded.

Against influenza they were 80% (95% CI 56% to 91%) efficacious when content matched WHO recommendations and circulating strain but decreased to 50% (95% CI 27% to 65%) when it did not (Comparison 01 02). Efficacy was lower (74%, 95% CI 45% to 87%) when the studies carried out during the 1968 to 1969 pandemic were excluded. Based on one study, 42% less (95% CI 9% to 63%) physician visits are carried out in those vaccinated with WHO recommended vaccines matching circulating viruses, but not in those not matching (RR 1.28, 95% CI 0.90 to 1.83) (Comparison 01 03). A similar result is seen in the effect on days of illness (Comparison 01 04), but there seems to be no effect on times an antibiotic or a drug were prescribed (Comparisons 01 05 and 01 06). Five trials evaluated time off work, estimating that vaccination saved on average around 0.13 working days. This result was not statistically significant. Hospital admissions (evaluated in four trials) were also lower in vaccinated arms, but the difference was not statistically significant. There was little difference in complication rates between vaccinated and unvaccinated groups (Comparisons 01 07 to 01 10). The conclusions of this comparison were unaffected by analysis using either random- or fixed-effect models

 

Harms

Local tenderness and soreness was more than twice as common among parenteral vaccine recipients than those in the placebo group (RR 3.11, 95% CI 2.08 to 4.66). There were also increases in erythema (RR 4.01, 95% CI 1.91 to 8.41), but not induration or arm stiffness. The combined local effects endpoint was significantly higher for those receiving the vaccine (RR 2.87, 95% CI 2.02 to 4.06). Myalgia was significantly associated with vaccination (RR 1.54, 95% CI 1.12 to 2.11). No other of the systemic effects were individually more common in parenteral vaccine recipients than in placebo recipients. However, the combined endpoint was increased (RR 1.29, 95% CI 1.01 to 1.64).

 

Live aerosol vaccines (Comparison 02)

Live aerosol vaccines have an effectiveness of 10% (95% CI 4% to 16%) and content and matching appear not to affect their performance significantly. However overall their efficacy is 62% (95% CI 45% to 73%). Again, neither content nor matching appear to affect their performance significantly. The effectiveness of the aerosol vaccines against influenza-like illness (with no clear definition) was significant only for WHO recommended and matched vaccine (47%, 95% CI 20% to 51%). Only one trial considered death as an outcome and did not register any event. The conclusions of this comparison were unaffected by analysis using either random- or fixed-effect models.

 

Harms

Significantly more recipients experienced symptoms of upper respiratory infection, sore throats and coryza after vaccine administration than placebo administration (upper respiratory infection RR 1.66, 95% CI 1.22 to 2.27; coryza RR 1.56, 95% CI 1.26 to 1.94; sore throat 1.73, 95% CI 1.44 to 2.08)). There was no significant increase in systemic harms, although rates of fever fatigue and myalgia were higher in vaccine than placebo groups.

 

Inactivated aerosol vaccines (Comparison 03)

Inactivated aerosol vaccines had effectiveness of 42% (95% CI 17% to 60%) although this observations is based on four datasets from two studies. The conclusions of this comparison were substantially unaffected by analysis using either random- or fixed-effect models although effectiveness against influenza-like illness - WHO recommended content and matching vaccine went from a fixed-effect RR 0.59 (95% CI 0.43 to 0.81) to a random-effects RR of 0.47 (95% CI 0.19 to 1.13) and the subcomparison influenza-like illness - WHO recommended but with content and matching unknown went from a fixed-effect RR 0.69 (95% CI 0.51 to 0.93) to a random-effects RR 0.63 (95% CI 0.37 to 1.07).

We conclude that the presence of heterogeneity does not materially alter our conclusions. Sensitivity analysis by methodological study quality did not affect our findings.

 

Harms

None of the trials on inactivated aerosol vaccines reported significant harms.

 

Serious and rare harms

 
Oculo-respiratory syndrome (ORS)

On the basis of one randomised trial (Scheifele 2003) on 651 healthy adults aged around 45, trivalent split inactivated vaccine (TIV) causes mild oculo-respiratory syndrome in people with no previous history of ORS. ORS was defined as bilateral conjunctivitis, facial swelling (lip, lid or mouth), difficulty in breathing and chest discomfort (including cough, wheeze, dysphagia or sore throat). ORS (attributable risk 2.9%, 95% CI 0.6 to 5.2), hoarseness (1.3%, 95% CI 0.3 to 1.3) and coughing (1.2%, 95% CI 0.2 to 1.6) occurred within six days of vaccination. The association did not appear to be specific for any type of TIV.

 
Guillain-Barré syndrome (GBS)

Three studies assessed the association between influenza vaccination and Guillain-Barré Syndrome (GBS) (rapidly progressing symmetric paralysis with usually spontaneous resolution). The first study compared GBS cases by vaccination status and the national incidence in vaccinated and unvaccinated national cohorts. The attributable risk from vaccination was just below 1 case of GBS every 100,000 vaccinations (Shoenberger 1979). The rise in GBS following rapid immunisation of millions of Americans in 1976 to 1977 led to the halting of the campaign. The second study (Kaplan 1982) was a retrospective cohort model comparing incidence of GBS in vaccinated and unvaccinated adults in the US (minus the state of Maryland) within eight weeks from vaccination. The study reported a lack of evidence of association (RR of 0.6 and 1.4 for the two seasons included in the study; described as non-significant but with no confidence intervals reported). The study is a poor quality model with poor case ascertainment, no case definition and assumptions of the size of the exposed and non exposed denominators. A similar design but with more sophistication was used in the Lasky et al study for the 1992 to 1993 and 1993 to 1994 seasons (Lasky 1998). Lasky et al. assessed the risk of GBS within 6 weeks from vaccination. Assessment of exposure was based on a random digit phone sample validated through state data on vaccine coverage and provider-sources data on vaccination timings. Two hundred and seventy three cases of GBS were identified through the CDC VAERS surveillance database and histories validated using hospital documentation. Only 180 cases were available for interview. Nineteen cases were assessed by the authors as being vaccine-associated (received vaccine in the previous six weeks (RR 1.8, 95% CI 1.0 to 3.5) adjusted for age, sex and season). The cases had a mean age of 66 years. The authors estimated the incidence of vaccine-induced GBS as 0.145 cases per million persons per week or 1.6 extra cases per million vaccinations. Despite its many limitations (mainly due to case attrition and variable reliability of exposure data) the study is well conducted and its conclusions credible, if conservative. We conclude that there may be a small additional risk of GBS. The studies demonstrate the danger of commencing a large vaccination campaign without adequate harms assessment.

 
Demyelinating diseases

Based on two case-control studies there is no evidence of an association between influenza vaccine and demylelinating disease (Payne 2006; DeStefano 2003).

 
Bell's palsy

One case-control study and case-series based in the German-speaking regions of Switzerland assessed association between an intranasal inactivated virosomal influenza vaccine and Bell's palsy (Mutsch 2004). Two hundred and fifty cases that could be evaluated (from an original 773 cases identified) were matched to 722 controls. All were aged around 50. The study reports a massive increase in risk (adjusted OR 84, 95% CI 20.1 to 351.9) within 1 to 91 days since vaccination. Despite its many limitations (case attrition - 187 cases could not be identified - and ascertainment bias - physicians picked controls for their own cases - confounding by indication - different vaccine exposure rate between controls and the reference population) it is unlikely that such a large OR could have been affected significantly by systematic error. The authors called for larger pre-licence harms trials, given the rarity of Bell's palsy. On the basis of this study the vaccine was withdrawn from commerce.

 
Cutaneous melanoma

The association between influenza vaccines and cutaneous melanoma was assessed by a case-control study on 99 cases and 104 controls (Mastrangelo 2000). The authors report a protective effect of repeated influenza vaccination on the risk cutaneous melanoma (OR 0.43, 95% CI 0.19 to 1.00). The study is at high risk of bias because of the selective nature of cases (all patients in the authors' hospital), attrition bias (four cases and four controls eliminated because of "failure to collaborate", recall bias (up to five years exposure data were based on patients' recollection) and ascertainment bias (non-blinded exposure survey).

 
Primary cardiac arrest

The association between influenza vaccination the previous year and the risk of primary (i.e. occurring in people with no previous history of cardiac disease) cardiac arrest was assessed by a case-control study on 360 cases and 418 controls (Siscovick 2000). The authors concluded that vaccination is protective against primary cardiac arrest (OR 0.51, 95% CI 0.33 to 0.79). The difficulty of case ascertainment (77% of potential cases had no medical examiner report and/or autopsy), recall bias (spouses provided exposure data for 304 cases, while 56 survivor cases provided data jointly with their spouses) make the conclusions of this study unreliable. It is impossible to judge the reliability of this study because of a lack of details on the circulation of influenza in the study areas in the 12 months preceding cardiac arrest (the causal hypothesis is based on the effects of influenza infection on the oxygen supply to the myocardium through lung infection and inflammation).

 
Pulmonary function

The effects of different types of live attenuated cold recombinant influenza vaccination on pulmonary function were assessed by a double-blind placebo-controlled randomised trial on 72 healthy volunteers aged around 26 (Atmar 1990) (data on 17 asthmatics were not extracted). The authors report several non-significant drops in lung function up to seven days post-inoculation and a higher incidence of influenza like illness (17/46 versus 4/26) in the vaccinated arms.

 

Vaccines for the 1968 to 1969 (H3N2) influenza pandemic (Comparisons 04 to 08)

Five studies yielded 12 datasets (Eddy 1970; Mogabgab 1970a; Mogabgab 1970b; Sumarokow 1971; Waldman 1969a; Waldman 1969b; Waldman 1969c; Waldman 1969d; Waldman 1972a; Waldman 1972b; Waldman 1972c; Waldman 1972d). As one would expect, vaccine performance was poor when content did not match the pandemic strain (Comparison 04). However, 1-dose or two-dose monovalent whole-virion (i.e. containing dead complete viruses) vaccines achieved 65% (95% CI 52% to 75%) protection against influenza-like illness and 93% (95% CI 69% to 98%) protection against influenza, and 65% (95% CI 6% to 87%) against hospitalisations (Comparison 05). Approximately half a working day lost and half a day of illness were saved but no effect was observed against pneumonia. All comparisons except for influenza-like illness are based on a single study (Comparison 05). The large effect on influenza-like illness is coherent with the high proportion of these illnesses caused by influenza viruses in a pandemic (i.e. the gap between efficacy and effectiveness of the vaccines is narrow). Aerosol polyvalent or monovalent vaccines had modest performance (Comparisons 06 to 08).

 

Discussion

  1. Top of page
  2. Background
  3. Objectives
  4. Methods
  5. Results
  6. Discussion
  7. Authors' conclusions
  8. Acknowledgements
  9. Data and analyses
  10. Appendices
  11. Feedback
  12. What's new
  13. History
  14. Contributions of authors
  15. Declarations of interest
  16. Sources of support
  17. Index terms

Although this review presents a large number of comparisons and outcomes based on a number of different groupings of studies and trials, the mainstream of the discussion was based on the results of the analysis of a WHO recommended vaccine against placebo. Parenterally administered influenza vaccines appear significantly better than their comparators and can reduce the incidence of influenza by around 80%, if the WHO recommendations are adhered to and the match is right. However, whilst the vaccines do prevent influenza, this is only one part of the spectrum of "clinical effectiveness" as they reduce total "clinical" seasonal influenza ( i.e. influenza-like illness) rates by around 15%. It is not possible to give a definite indication on the practical use of live aerosol vaccines, because the assessment of their effectiveness is based on a limited number of studies presenting conflicting results. The effectiveness, according to WHO criteria, appears relatively low. Results regarding inactivated aerosol vaccine are based on the analysis of a few trials reporting only clinical outcomes not directly comparable, owing to non-homogeneous definitions. It does not seem wise to draw conclusions from these data. Rates of complications caused by influenza in these trials were very low and analysis of the few trials which contained this outcome, did not reveal a significant reduction with the influenza vaccine. This result appears to contrast with assertions of policy makers (ACIP 2006) and may be due to the general rarity of complications caused by respiratory infection in healthy adults. Hospitalisation was assessed in four trials and did not show a significant benefit from vaccination. Working days lost in placebo recipient and vaccine recipients were significantly reduced in the vaccinated group, but by less than half a day on average.

Inactivated vaccines cause local (redness, induration) and systemic harms (myalgia, possibly fatigue). In rare cases there may be an increased risk of GBS, of ORS and Bell's palsy but this may be product-specific. Given the low effectiveness of the aerosol vaccines, the effects classified as harms (sore throat and cough) may be caused by influenza. Although the possibility of causing serious harm may be rare, it must be born in mind when proposing the inception of a mass campaign of immunisation to a whole population, i.e. when exposure to the vaccines is increased manyfold.

While the parenteral vaccine efficacy against seasonal (i.e. non-pandemic) influenza is around 75% for the WHO recommended and matched strain, its impact on the global incidence of clinical cases of influenza (i.e. influenza-like illness) is limited (around 16% in best case scenario). The universal immunisation of healthy adults should achieve a number of specific goals: reducing the spread of the disease, reducing the economic loss due to working days lost and reducing morbidity and hospitalisation. None of the studies included in the review presented results evaluating the ability of this vaccination to interrupt the spread of the disease. Some studies presented data on reduction of working days lost and showed a very limited effect. Similarly a very limited effect was found on morbidity and no effect was found on hospitalisation. Given the limited availability of resources for mass immunisation, the use of influenza vaccines should be primarily directed where there is clear evidence of benefit.

Whole-virion monovalent inactivated vaccines may help control a pandemic, if the antigenic match between virus and vaccine is right. Although this observation is based on a limited number of old trials, the high effectiveness of the vaccine (i.e. against influenza-like illness) would seem to confirm its potential for use. Efforts to update and enhance these vaccines should have priority.

A number of problems should be taken into consideration when interpreting the results of this review.

  1. None of the live aerosol vaccines included in the review were registered.
  2. Methods of vaccine standardisation have changed significantly.
  3. Recent vaccines present significant differences in purity when compared with older ones.
  4. Different doses and schedules were pooled in the analysis.

 

Authors' conclusions

  1. Top of page
  2. Background
  3. Objectives
  4. Methods
  5. Results
  6. Discussion
  7. Authors' conclusions
  8. Acknowledgements
  9. Data and analyses
  10. Appendices
  11. Feedback
  12. What's new
  13. History
  14. Contributions of authors
  15. Declarations of interest
  16. Sources of support
  17. Index terms

 

Implications for practice

The results of this review seem to discourage the utilisation of vaccination against influenza in healthy adults as a routine public health measure. As healthy adults have a low risk of complications due to respiratory disease, the use of the vaccine may be only advised as an individual protection measure in specific cases.

 
Implications for research

The major differences in effect size between outcomes highlight the need for careful consideration of the best study design to assess the effects of public health measures such as vaccines. Large studies encompassing several influenza seasons are required to allow assessment of the effect of the vaccines on seemingly rare outcomes such as complications and death.

 

Acknowledgements

  1. Top of page
  2. Background
  3. Objectives
  4. Methods
  5. Results
  6. Discussion
  7. Authors' conclusions
  8. Acknowledgements
  9. Data and analyses
  10. Appendices
  11. Feedback
  12. What's new
  13. History
  14. Contributions of authors
  15. Declarations of interest
  16. Sources of support
  17. Index terms

The authors gratefully acknowledge the help received from Drs Brian Hutchison, Alan Hampson, James Irlam, Andy Oxman and Barbara Treacy. The authors would like to thank also the help received in updating the review by Gabriella Morandi. While the original review was funded by the UK Ministry of Defence, the 2004 update was supported by the two Italian Local Health Authorities in which two of the review authors are employed. The 2006 update was funded by the same Local Health Authorities and the UK's Department of Health Cochrane Incentive Scheme. Professor Jon Deeks designed and carried out statistical analyses in earlier versions of the review. Finally, the authors wish to thank Kathie Clark, Hans van der Wouden, Nelcy Rodriguez and Leonard Leibovici for commenting on this 2006 update.

 

Data and analyses

  1. Top of page
  2. Background
  3. Objectives
  4. Methods
  5. Results
  6. Discussion
  7. Authors' conclusions
  8. Acknowledgements
  9. Data and analyses
  10. Appendices
  11. Feedback
  12. What's new
  13. History
  14. Contributions of authors
  15. Declarations of interest
  16. Sources of support
  17. Index terms
Download statistical data

 
Comparison 1. Inactivated parenteral vaccine versus placebo or do-nothing

Outcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size

 1 Influenza-like illness2013125Risk Ratio (M-H, Random, 95% CI)0.77 [0.68, 0.87]

    1.1 WHO recommended - matching vaccine
106984Risk Ratio (M-H, Random, 95% CI)0.70 [0.59, 0.83]

    1.2 WHO recommended - vaccine matching absent or unknown
86048Risk Ratio (M-H, Random, 95% CI)0.88 [0.72, 1.08]

    1.3 Monovalent not WHO recommended - vaccine matching
159Risk Ratio (M-H, Random, 95% CI)1.02 [0.28, 3.70]

    1.4 Monovalent not WHO recommended - vaccine matching - high dose
134Risk Ratio (M-H, Random, 95% CI)0.46 [0.09, 2.30]

 2 Influenza1517530Risk Ratio (M-H, Random, 95% CI)0.35 [0.25, 0.49]

    2.1 WHO recommended - matching vaccine
73633Risk Ratio (M-H, Random, 95% CI)0.20 [0.09, 0.44]

    2.2 WHO recommended - vaccine matching absent or unknown
54188Risk Ratio (M-H, Random, 95% CI)0.50 [0.35, 0.73]

    2.3 Monovalent not WHO recommended - vaccine matching
29675Risk Ratio (M-H, Random, 95% CI)0.22 [0.10, 0.52]

    2.4 Monovalent not WHO recommended - vaccine matching - high dose
134Risk Ratio (M-H, Random, 95% CI)0.11 [0.00, 2.49]

 3 Physician visits22308Risk Ratio (M-H, Random, 95% CI)0.87 [0.40, 1.89]

    3.1 WHO recommended - matching vaccine
11178Risk Ratio (M-H, Random, 95% CI)0.58 [0.37, 0.91]

    3.2 WHO recommended - vaccine matching absent or unknown
11130Risk Ratio (M-H, Random, 95% CI)1.28 [0.90, 1.83]

 4 Days ill44800Mean Difference (IV, Random, 95% CI)-0.29 [-0.72, 0.15]

    4.1 WHO recommended - matching vaccine
33670Mean Difference (IV, Random, 95% CI)-0.48 [-0.62, -0.34]

    4.2 WHO recommended - matching absent or unknown
11130Mean Difference (IV, Random, 95% CI)0.66 [0.16, 1.16]

 5 Times any drugs were prescribed22308Mean Difference (IV, Random, 95% CI)-0.01 [-0.03, 0.01]

    5.1 WHO recommended - matching vaccine
11178Mean Difference (IV, Random, 95% CI)-0.02 [-0.04, -0.00]

    5.2 WHO recommended - matching absent or unknown
11130Mean Difference (IV, Random, 95% CI)Not estimable

 6 Times antibiotic was prescribed22308Mean Difference (IV, Random, 95% CI)-0.02 [-0.03, -0.01]

    6.1 WHO recommended - matching vaccine
11178Mean Difference (IV, Random, 95% CI)-0.02 [-0.03, -0.01]

    6.2 WHO recommended - matching absent or unknown
11130Mean Difference (IV, Random, 95% CI)-0.01 [-0.03, 0.01]

 7 Working days lost55393Mean Difference (IV, Random, 95% CI)-0.13 [-0.25, -0.00]

    7.1 WHO recommended - matching vaccine
44263Mean Difference (IV, Random, 95% CI)-0.21 [-0.36, -0.05]

    7.2 WHO recommended - matching absent or unknown
11130Mean Difference (IV, Random, 95% CI)0.09 [0.00, 0.18]

 8 Hospitalisations514877Risk Ratio (M-H, Random, 95% CI)0.89 [0.65, 1.20]

    8.1 WHO recommended - matching vaccine
22580Risk Ratio (M-H, Random, 95% CI)0.37 [0.12, 1.12]

    8.2 WHO recommended - vaccine matching absent or unknown
22681Risk Ratio (M-H, Random, 95% CI)0.85 [0.38, 1.91]

    8.3 Monovalent not WHO recommended - vaccine matching
19616Risk Ratio (M-H, Random, 95% CI)0.96 [0.85, 1.08]

 9 Pneumonia22953Risk Ratio (M-H, Random, 95% CI)0.80 [0.13, 4.93]

    9.1 WHO recommended - matching vaccine
11402Risk Ratio (M-H, Random, 95% CI)0.59 [0.04, 9.43]

    9.2 WHO recommended - vaccine matching absent or unknown
11551Risk Ratio (M-H, Random, 95% CI)1.01 [0.09, 11.13]

 10 Clinical cases (clinically defined without clear definition)45926Risk Ratio (M-H, Random, 95% CI)0.63 [0.41, 0.99]

    10.1 WHO recommended - matching vaccine
33723Risk Ratio (M-H, Random, 95% CI)0.56 [0.27, 1.16]

    10.2 WHO recommended - vaccine matching absent or unknown
12203Risk Ratio (M-H, Random, 95% CI)0.83 [0.69, 0.99]

 11 Local harms16Risk Ratio (M-H, Random, 95% CI)Subtotals only

    11.1 Local - tenderness/soreness
146833Risk Ratio (M-H, Random, 95% CI)3.11 [2.08, 4.66]

    11.2 Local - erythema
63388Risk Ratio (M-H, Random, 95% CI)4.01 [1.91, 8.41]

    11.3 Local - induration
2543Risk Ratio (M-H, Random, 95% CI)2.24 [0.48, 10.59]

    11.4 Local - arm stiffness
150Risk Ratio (M-H, Random, 95% CI)1.62 [0.54, 4.83]

    11.5 Local - combined endpoint (any or highest symptom)
125171Risk Ratio (M-H, Random, 95% CI)2.87 [2.02, 4.06]

 12 Systemic harms13Risk Ratio (M-H, Random, 95% CI)Subtotals only

    12.1 Systemic - myalgia
52676Risk Ratio (M-H, Random, 95% CI)1.54 [1.12, 2.11]

    12.2 Systemic - fever
82775Risk Ratio (M-H, Random, 95% CI)1.17 [0.80, 1.72]

    12.3 Systemic - headache
83667Risk Ratio (M-H, Random, 95% CI)1.30 [0.84, 2.03]

    12.4 Systemic - fatigue or indisposition
63456Risk Ratio (M-H, Random, 95% CI)1.37 [0.94, 2.02]

    12.5 Systemic - nausea/vomiting
31667Risk Ratio (M-H, Random, 95% CI)2.68 [0.55, 13.08]

    12.6 Systemic - combined endpoint (any or highest symptom)
82603Risk Ratio (M-H, Random, 95% CI)1.29 [1.01, 1.64]

 
Comparison 2. Live aerosol vaccine versus placebo or do-nothing

Outcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size

 1 Influenza-like illness612688Risk Ratio (M-H, Random, 95% CI)0.90 [0.84, 0.96]

    1.1 WHO recommended - matching vaccine
24254Risk Ratio (M-H, Random, 95% CI)0.92 [0.76, 1.12]

    1.2 WHO recommended - vaccine matching absent or unknown
38150Risk Ratio (M-H, Random, 95% CI)0.89 [0.82, 0.97]

    1.3 Non WHO recommended - vaccine matching absent or unknown
1284Risk Ratio (M-H, Random, 95% CI)0.92 [0.73, 1.16]

 2 Influenza68524Risk Ratio (M-H, Random, 95% CI)0.38 [0.27, 0.55]

    2.1 WHO recommended - matching vaccine
24254Risk Ratio (M-H, Random, 95% CI)0.44 [0.24, 0.81]

    2.2 WHO recommended - vaccine matching absent or unknown
23843Risk Ratio (M-H, Random, 95% CI)0.36 [0.16, 0.82]

    2.3 Non WHO recommended - vaccine matching absent or unknown
2427Risk Ratio (M-H, Random, 95% CI)0.21 [0.08, 0.56]

 3 Complications (bronchitis, otitis, pneumonia)119887Risk Ratio (M-H, Random, 95% CI)0.25 [0.03, 2.24]

    3.1 Non WHO recommended - vaccine matching absent or unknown
119887Risk Ratio (M-H, Random, 95% CI)0.25 [0.03, 2.24]

 4 Influenza cases (clinically defined without clear definition)323900Risk Ratio (M-H, Random, 95% CI)0.89 [0.71, 1.11]

    4.1 WHO recommended - matching vaccine
11931Risk Ratio (M-H, Random, 95% CI)0.63 [0.49, 0.80]

    4.2 WHO recommended - vaccine matching absent or unknown
12082Risk Ratio (M-H, Random, 95% CI)1.05 [0.88, 1.25]

    4.3 Non WHO recommended - vaccine matching absent or unknown
119887Risk Ratio (M-H, Random, 95% CI)0.98 [0.92, 1.05]

 5 Local harms11Risk Ratio (M-H, Random, 95% CI)Subtotals only

    5.1 Local - upper respiratory infection symptoms
6496Risk Ratio (M-H, Random, 95% CI)1.66 [1.22, 2.27]

    5.2 Local - cough
4852Risk Ratio (M-H, Random, 95% CI)1.24 [0.69, 2.22]

    5.3 Local - coryza
24782Risk Ratio (M-H, Random, 95% CI)1.56 [1.26, 1.94]

    5.4 Local - sore throat
55391Risk Ratio (M-H, Random, 95% CI)1.73 [1.44, 2.08]

    5.5 Local - hoarseness
1306Risk Ratio (M-H, Random, 95% CI)1.21 [0.51, 2.83]

    5.6 Local - combined endpoint (any or highest symptom)
34921Risk Ratio (M-H, Random, 95% CI)1.56 [1.31, 1.87]

 6 Systemic harms6Risk Ratio (M-H, Random, 95% CI)Subtotals only

    6.1 Systemic - myalgia
3713Risk Ratio (M-H, Random, 95% CI)2.28 [0.81, 6.45]

    6.2 Systemic - fever
3713Risk Ratio (M-H, Random, 95% CI)1.28 [0.43, 3.79]

    6.3 Systemic - fatigue or indisposition
2413Risk Ratio (M-H, Random, 95% CI)1.52 [0.66, 3.49]

    6.4 Systemic - headache
1370Risk Ratio (M-H, Random, 95% CI)2.33 [0.52, 10.33]

    6.5 Systemic - combined endpoint (any or highest symptom)
51018Risk Ratio (M-H, Random, 95% CI)1.40 [0.82, 2.38]

 
Comparison 3. Inactivated aerosol vaccine versus placebo or do-nothing

Outcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size

 1 Influenza-like illness41674Risk Ratio (M-H, Random, 95% CI)0.58 [0.40, 0.83]

    1.1 WHO recommended - matching vaccine
2841Risk Ratio (M-H, Random, 95% CI)0.47 [0.19, 1.13]

    1.2 WHO recommended - vaccine matching absent or unknown
2833Risk Ratio (M-H, Random, 95% CI)0.63 [0.37, 1.07]

 2 Local harms4716Risk Ratio (M-H, Random, 95% CI)1.09 [0.85, 1.40]

    2.1 Local - sore throat
2151Risk Ratio (M-H, Random, 95% CI)0.82 [0.43, 1.56]

    2.2 Local - combined endpoint (any or highest symptom)
3565Risk Ratio (M-H, Random, 95% CI)1.15 [0.88, 1.50]

 3 Systemic harms41018Risk Ratio (M-H, Random, 95% CI)1.00 [0.77, 1.31]

    3.1 Systemic - myalgia
2151Risk Ratio (M-H, Random, 95% CI)0.90 [0.36, 2.25]

    3.2 Systemic - fatigue or indisposition
2151Risk Ratio (M-H, Random, 95% CI)1.40 [0.52, 3.75]

    3.3 Systemic - headache
2151Risk Ratio (M-H, Random, 95% CI)1.52 [0.85, 2.72]

    3.4 Systemic - combined endpoint (any or highest symptom)
3565Risk Ratio (M-H, Random, 95% CI)0.83 [0.54, 1.27]

 
Comparison 4. 1968 to 1969 pandemic: Inactivated polyvalent parenteral vaccine versus placebo

Outcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size

 1 Influenza-like illness33065Risk Ratio (M-H, Random, 95% CI)0.71 [0.57, 0.88]

    1.1 Standard recommended parenteral - non matching - 1 dose
32715Risk Ratio (M-H, Random, 95% CI)0.74 [0.57, 0.95]

    1.2 Standard recommended parenteral - non matching - 2 doses
1350Risk Ratio (M-H, Random, 95% CI)0.66 [0.44, 0.98]

 2 Influenza12072Risk Ratio (M-H, Random, 95% CI)0.47 [0.26, 0.87]

    2.1 Standard recommended parenteral - non matching
12072Risk Ratio (M-H, Random, 95% CI)0.47 [0.26, 0.87]

 3 Hospitalisations12072Risk Ratio (M-H, Random, 95% CI)0.83 [0.41, 1.68]

    3.1 Standard recommended parenteral - non matching
12072Risk Ratio (M-H, Random, 95% CI)0.83 [0.41, 1.68]

 4 Pneumonia12072Risk Ratio (M-H, Random, 95% CI)1.01 [0.14, 7.17]

    4.1 Standard recommended parenteral - non matching
12072Risk Ratio (M-H, Random, 95% CI)1.01 [0.14, 7.17]

 
Comparison 5. 1968 to 1969 pandemic: Inactivated monovalent parenteral vaccine versus placebo

Outcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size

 1 Influenza-like illness44580Risk Ratio (M-H, Random, 95% CI)0.35 [0.25, 0.48]

    1.1 WHO recommended parenteral - matching vaccine - 1 dose
44226Risk Ratio (M-H, Random, 95% CI)0.35 [0.23, 0.53]

    1.2 WHO recommended parenteral - matching vaccine - 2 doses
1354Risk Ratio (M-H, Random, 95% CI)0.35 [0.22, 0.57]

 2 Influenza11923Risk Ratio (M-H, Random, 95% CI)0.07 [0.02, 0.31]

    2.1 WHO recommended parenteral - matching vaccine
11923Risk Ratio (M-H, Random, 95% CI)0.07 [0.02, 0.31]

 3 Hospitalisations11923Risk Ratio (M-H, Random, 95% CI)0.35 [0.13, 0.94]

    3.1 WHO recommended parenteral - matching vaccine
11923Risk Ratio (M-H, Random, 95% CI)0.35 [0.13, 0.94]

 4 Pneumonia11923Risk Ratio (M-H, Random, 95% CI)0.59 [0.05, 6.51]

    4.1 WHO recommended parenteral - matching vaccine
11923Risk Ratio (M-H, Random, 95% CI)0.59 [0.05, 6.51]

 5 Working days lost11667Mean Difference (IV, Random, 95% CI)-0.45 [-0.60, -0.30]

    5.1 WHO recommended parenteral - matching vaccine
11667Mean Difference (IV, Random, 95% CI)-0.45 [-0.60, -0.30]

 6 Days ill11667Mean Difference (IV, Random, 95% CI)-0.45 [-0.60, -0.30]

    6.1 WHO recommended - matching vaccine
11667Mean Difference (IV, Random, 95% CI)-0.45 [-0.60, -0.30]

 
Comparison 6. 1968 to 1969 pandemic: Inactivated polyvalent aerosol vaccine versus placebo

Outcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size

 1 Influenza-like illness21000Risk Ratio (M-H, Random, 95% CI)0.66 [0.46, 0.95]

    1.1 Inactivated polyvalent aerosol vaccine versus placebo - non matching - 1 dose
2644Risk Ratio (M-H, Random, 95% CI)0.64 [0.32, 1.27]

    1.2 Inactivated polyvalent aerosol vaccine versus placebo - non matching - 2 doses
1356Risk Ratio (M-H, Random, 95% CI)0.65 [0.44, 0.97]

 
Comparison 7. 1968 to 1969 pandemic: Inactivated monovalent aerosol vaccine versus placebo

Outcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size

 1 Influenza-like illness21009Risk Ratio (M-H, Random, 95% CI)0.54 [0.32, 0.91]

    1.1 Inactivated monovalent aerosol vaccine versus placebo - matching - 1 dose
2650Risk Ratio (M-H, Random, 95% CI)0.49 [0.17, 1.41]

    1.2 Inactivated monovalent aerosol vaccine versus placebo - matching - 2 doses
1359Risk Ratio (M-H, Random, 95% CI)0.57 [0.38, 0.86]

 
Comparison 8. 1968 to 1969 pandemic: Live aerosol vaccine versus placebo

Outcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size

 1 Influenza cases (clinically defined without clear definition)119887Risk Ratio (M-H, Random, 95% CI)0.98 [0.92, 1.05]

    1.1 Non matching
119887Risk Ratio (M-H, Random, 95% CI)0.98 [0.92, 1.05]

 2 Complications (bronchitis, otitis, pneumonia)119887Risk Ratio (M-H, Fixed, 95% CI)0.25 [0.03, 2.24]

    2.1 Non matching
119887Risk Ratio (M-H, Fixed, 95% CI)0.25 [0.03, 2.24]

 

Appendices

  1. Top of page
  2. Background
  3. Objectives
  4. Methods
  5. Results
  6. Discussion
  7. Authors' conclusions
  8. Acknowledgements
  9. Data and analyses
  10. Appendices
  11. Feedback
  12. What's new
  13. History
  14. Contributions of authors
  15. Declarations of interest
  16. Sources of support
  17. Index terms
 

Appendix 1. MEDLINE search strategy for 2004 update

MEDLINE
#1 ("Influenza Vaccine/administration and dosage"[MeSH] OR "Influenza Vaccine/adverse effects"[MeSH] OR "Influenza Vaccine/contraindications"[MeSH] OR "Influenza Vaccine/immunology"[MeSH] OR "Influenza Vaccine/metabolism"[MeSH] OR "Influenza Vaccine/radiation effects"[MeSH] OR "Influenza Vaccine/therapeutic use"[MeSH] OR "Influenza Vaccine/toxicity"[MeSH]) OR ("Influenza/epidemiology"[MeSH] OR "Influenza/immunology"[MeSH] OR "Influenza/mortality"[MeSH] OR "Influenza/prevention and control"[MeSH] OR "Influenza/transmission"[MeSH])
#2 (influenza vaccin*[Title/Abstract]) OR ((influenza [Title/Abstract] OR flu[Title/Abstract]) AND (vaccin*[Title/Abstract] OR immuni*[Title/Abstract] OR inoculati*[Title/Abstract] OR efficacy[Title/Abstract] OR effectiveness[Title/Abstract])
#3 #1 OR #2
# 4 "Randomized Controlled Trial"[Publication Type] OR "Randomized Controlled Trials"[MeSH] OR "Controlled Clinical Trial"[Publication Type] OR "Controlled Clinical Trials"[MeSH] OR "Random Allocation"[MeSH] OR "Double-Blind Method"[MeSH] OR "Single-Blind Method"[MeSH]
#5 controlled clinical trial*[Title/Abstract] OR randomised controlled trial*[Title/Abstract] OR clinical trial*[Title/Abstract] OR random allocation[Title/Abstract] OR random*[Title/Abstract] OR placebo[Title/Abstract] OR double - blind[Title/Abstract] OR single - blind[Title/Abstract] OR RCT[Title/Abstract] OR CCT[Title/Abstract] OR allocation[Title/Abstract] OR follow - up[Title/Abstract]
#6 #4 OR #5
#7 #3 AND #6

 

Feedback

  1. Top of page
  2. Background
  3. Objectives
  4. Methods
  5. Results
  6. Discussion
  7. Authors' conclusions
  8. Acknowledgements
  9. Data and analyses
  10. Appendices
  11. Feedback
  12. What's new
  13. History
  14. Contributions of authors
  15. Declarations of interest
  16. Sources of support
  17. Index terms
 

Inconsistency between results and abstract

 

Summary

We feel there is some inconsistency between results and abstract of this review regarding off work time.

In the results it states that 0.4 days are saved, but that this result is not statistically significant. In the abstract, however, this difference is labelled significant. Can you help us in understanding this?

I certify that I have no affiliations with or involvement in any organisation or entity with a direct financial interest in the subject matter of my criticisms.

 

Reply

The difference is statistically significat as it says in the abstract. In the results the word "statistical" has been used instead of "clinical". Indeed the meaning of the comment was to underline that, although statistically significant, a difference of 0.4 day is clinically inconsistent.

I certify that I have no affiliations with or involvement in any organisation or entity with a direct financial interest in the subject matter of my criticisms

Vittorio Demicheli

 

Contributors

JC van der Wouden
Feedback added 16/04/07

 

Comments regarding the conclusion

 

Summary

Your conclusion is confusing. You write: "Universal immunization of healthy adults is not supported by the results of this review." If so, why the first sentence? You wrote in the Discussion that "serologically confirmed cases of influenza are only part of the spectum of clinical effectiveness." Furthermore, it would be helpful if you had explained the difference between influenza and influenza-like illness in the abstract. Also, the title of the synopsis is inaccurate. Why say "not enough evidence" when there are so many trials in your review? It should read: Clinical trials do not support the universal recommendation, etc. And "by a quarter" is not going to be understood by the general public. Please put in absolute terms.

I certify that I have no affiliations with or involvement in any organization or entity with a financial interest in the subject matter of my feedback.

 

Reply

This comment has been superseded and addressed by the 2006 latest update.

 

Contributors

Maryann Napoli
Feedback added 05/04/06

 

What's new

  1. Top of page
  2. Background
  3. Objectives
  4. Methods
  5. Results
  6. Discussion
  7. Authors' conclusions
  8. Acknowledgements
  9. Data and analyses
  10. Appendices
  11. Feedback
  12. What's new
  13. History
  14. Contributions of authors
  15. Declarations of interest
  16. Sources of support
  17. Index terms

Last assessed as up-to-date: 8 January 2006.


DateEventDescription

10 May 2009AmendedContact details updated.



 

History

  1. Top of page
  2. Background
  3. Objectives
  4. Methods
  5. Results
  6. Discussion
  7. Authors' conclusions
  8. Acknowledgements
  9. Data and analyses
  10. Appendices
  11. Feedback
  12. What's new
  13. History
  14. Contributions of authors
  15. Declarations of interest
  16. Sources of support
  17. Index terms

Protocol first published: Issue 4, 1998
Review first published: Issue 4, 1999


DateEventDescription

26 April 2008AmendedConverted to new review format.

15 April 2007Feedback has been incorporatedFeedback added to review

20 November 2006New citation required and conclusions have changedSubstantive amendment

4 April 2006Feedback has been incorporatedFeedback commented added to review.

9 January 2006New search has been performedSearches conducted.

30 November 2003New search has been performedSearches conducted.

27 December 1997New search has been performedSearches conducted.



 

Contributions of authors

  1. Top of page
  2. Background
  3. Objectives
  4. Methods
  5. Results
  6. Discussion
  7. Authors' conclusions
  8. Acknowledgements
  9. Data and analyses
  10. Appendices
  11. Feedback
  12. What's new
  13. History
  14. Contributions of authors
  15. Declarations of interest
  16. Sources of support
  17. Index terms

For the 2006 update Tom Jefferson (TJ), Daniela Rivetti (DR) and and Vittorio Demicheli (VD) designed the update.
TJ and DR wrote the protocol, Alessandro Rivetti (AR) carried out the searches.
TJ and DR applied inclusion criteria.
TJ, DR and AR extracted data.
Carlo Di Pietrantonj (CDP) arbitrated and checked the data extraction.
CDP and DR performed the meta-analysis and carried out statistical testing.
TJ and AR wrote the final report.
All authors contributed to both the protocol and final report.

Statistical support to previous review versions was provided by JJ Deeks.

 

Declarations of interest

  1. Top of page
  2. Background
  3. Objectives
  4. Methods
  5. Results
  6. Discussion
  7. Authors' conclusions
  8. Acknowledgements
  9. Data and analyses
  10. Appendices
  11. Feedback
  12. What's new
  13. History
  14. Contributions of authors
  15. Declarations of interest
  16. Sources of support
  17. Index terms

TJ owned shares in Glaxo SmithKline and received consultancy fees from Sanofi Synthelabo and Roche. All other authors have no conflicts to declare.

 

Glossary

 

Efficacy:

the impact of an intervention (drug, vaccines etc) on a problem or disease in ideal conditions - in this case the capacity of vaccines to prevent or treat influenza and its complications.

 

Effectiveness:

the impact of an intervention (drug, vaccines etc) on a problem or disease in field conditions - in this case the capacity of vaccines to prevent or treat ILI and its complications.

 

Influenza:

an acute respiratory infection caused by a virus of the Orthomyxoviridae family. Three serotypes are known (A, B and C). Influenza causes an acute febrile illness with myalgia, headache and cough. Although the median duration of the acute illness is three days, cough and malaise can persist for weeks. Complications of influenza include otitis media, pneumonia, secondary bacterial pneumonia, exacerbations of chronic respiratory disease and bronchiolitis in children. These illnesses may require treatment in a hospital and can be life-threatening especially in 'high-risk' people e.g. the elderly and people suffering from chronic heart disease. Additionally, influenza can cause a range of non-respiratory complications including febrile convulsions, Reye's syndrome and myocarditis. The influenza virus is composed of a protein envelope around an RNA core. On the envelope are two antigens: neuraminidase (N antigen) and hemagglutinin (H antigen). Hemagglutinin is an enzyme that facilitates the entry of the virus into cells of the respiratory epithelium, while neuraminidase facilitates the release of newly produced viral particles from infected cells. The influenza virus has a marked propensity to mutate its external antigenic composition to escape the hosts' immune defences. Given this extreme mutability, a classification of viral subtype A based on H and N typing has been introduced. Additionally, strains are classified on the basis of antigenic type of the nucleoprotein core (A, B ), geographical location of first isolation, strain serial number and year of isolation. Every item is separated by a slash mark (e.g. A/Wuhan/359/95 (H3N2)). Unless otherwise specified such strains are of human origin. The production of antibodies against influenza beyond a conventional quantitative threshold is called seroconversion. Seroconversion in the absence of symptoms is called asymptomatic influenza.

 

Influenza-like illness (ILI):

an acute respiratory illness caused by scores of different viruses (including influenza A and B) presenting with symptoms and signs which are not distinguishable from those of influenza. ILI does not have documented laboratory isolation of the causative agent and is what commonly presents to physicians and patients (also known as the flu").

 

Sources of support

  1. Top of page
  2. Background
  3. Objectives
  4. Methods
  5. Results
  6. Discussion
  7. Authors' conclusions
  8. Acknowledgements
  9. Data and analyses
  10. Appendices
  11. Feedback
  12. What's new
  13. History
  14. Contributions of authors
  15. Declarations of interest
  16. Sources of support
  17. Index terms
 

Internal sources

  • ASL 19 and 20, Piemonte, Italy.

 

External sources

  • Ministry of Defence, UK.
  • NHS Dept of Health Cochrane Incentive Scheme, UK.

References

References to studies included in this review

  1. Top of page
  2. Abstract
  3. Background
  4. Objectives
  5. Methods
  6. Results
  7. Discussion
  8. Authors' conclusions
  9. Acknowledgements
  10. Data and analyses
  11. Appendices
  12. Feedback
  13. What's new
  14. History
  15. Contributions of authors
  16. Declarations of interest
  17. Sources of support
  18. Characteristics of studies
  19. References to studies included in this review
  20. References to studies excluded from this review
  21. Additional references
  22. References to other published versions of this review
Atmar 1990 {published data only}
  • Atmar RL, Bloom K, Keitel W, Couch RB, Greenberg SB. Effect of live attenuated, cold recombinant (CR) influenza virus vaccines on pulmonary function in healthy and asthmatic adults. Vaccine 1990;8(3):217-24.
Betts 1977a {published data only}
  • Betts RF, Douglas RG Jr, Roth FK, Little JW 3rd. Efficacy of live attenuated influenza A/Scotland/74 (H3N2) virus vaccine against challenge with influenza A/Victoria/3/75 (H3N2) virus. Journal of Infectious Diseases 1977;136(6):746-53.
Boyce 2000 {published data only}
  • Boyce TG, Hsu HH, Sannella EC, Coleman-Dockery SD, Baylis E, Zhu Y, et al. Safety and immunogenicity of adjuvanted and unadjuvanted subunit influenza vaccines administered intranasally to healthy adults. Vaccine 2000;19(2-3):217-26.
Bridges 2000a {published data only}
  • Buxton Bridges C, Thompson VV, Meltzer MI, Reeve GR, Talamonti VJ, Cox NJ, et al. Effectiveness and cost benefit of influenza vaccination of healthy working adults, a randomized controlled trial. JAMA 2000;284(13):1655-63.
Bridges 2000b {published data only}
  • Buxton Bridges C, Thompson VV, Meltzer MI, Reeve GR, Talamonti VJ, Cox NJ. Effectiveness and cost benefit of influenza vaccination of healthy working adults, a randomized controlled trial. JAMA 2000;284(13):1655-63.
Caplan 1977 {published data only}
  • Caplan ES, Hughes TP, O'Donnel S, Levine MM, Hornick RB. Reactogenicity and immunogenicity of parenteral monovalent influenza A/Victoria/3/75 (H3N2) virus vaccine in healthy adults. Journal of Infectious Diseases 1977;136(Suppl):484-90.
DeStefano 2003 {published data only}
  • DeStefano F, Verstraeten T, Jackson LA, Okoro CA, Benson P, Black SB, et al. Vaccinations and risk of central nervous system demyelinating diseases in adults. Archives of Neurology 2003;60(4):504-9.
Eddy 1970 {published data only}
  • Eddy TS, Davies NA. The effect of vaccine on a closed epidemic of Hong Kong influenza. South African Medical Journal 1970;February 21:214-6.
Edwards 1994a {published data only}
  • Edwards KM, Dupont WD, Westrich MK, et al. A randomized controlled trial of cold adapted and inactivated vaccines for the prevention of influenza A disease. Journal of Infectious Diseases 1994;169:68-76.
Edwards 1994b {published data only}
  • Edwards KM, Dupont WD, Westrich MK, et al. A randomized controlled trial of cold adapted and inactivated vaccines for the prevention of influenza A disease. Journal of Infectious Diseases 1994;169:68-76.
Edwards 1994c {published data only}
  • Edwards KM, Dupont WD, Westrich MK, et al. A randomized controlled trial of cold adapted and inactivated vaccines for the prevention of influenza A disease. Journal of Infectious Diseases 1994;169:68-76.
Edwards 1994d {published data only}
  • Edwards KM, Dupont WD, Westrich MK, et al. A randomized controlled trial of cold adapted and inactivated vaccines for the prevention of influenza A disease. Journal of Infectious Diseases 1994;169:68-76.
El'shina 1996 {published data only}
  • El'shina GA, Masalin IuM, Shervali VI, Gorbunov MA, Lonskaia NI, Agafonova LV, et al. The trivalent polymer-subunit influenza vaccine Grippol studied in a controlled epidemiological trial. Voenno-Meditsinskii Zhurnal 1996;317(8):57-60.
Evans 1976 {published data only}
Forsyth 1967 {published data only}
Goodeve 1983 {published data only}
  • Goodeve A, Potter CW, Clark A, Jennings R, Schild GC, Yetts R. A graded-dose study of inactivated, surface antigen influenza B vaccine in volunteers: reactogenicity, antibody response and protection to challenge virus infection. Journal of Hygiene 1983;90(1):107-15.
Hammond 1978 {published data only}
  • Hammomd ML, Ferris AA, Faine S, et al. Effective protection against influenza after vaccination with subunit vaccine. Medical Journal of Australia 1978;1:301-3.
Hrabar 1977 {published data only}
  • Hrabar A, Vodopija I, Andre FE, Mitchell JR, Maassab HF, Hennessy AV, et al. A placebo-controlled dose-response study of the reactogenicity and immunogenicity of a cold-adapted recombinant A/Victoria/3/75 (H3N2) live influenza virus candidate vaccine in healthy volunteers. Developments in Biological Standardization 1977;39:53-60.
Kaplan 1982 {published data only}
  • Kaplan JE, Katona P, Hurwitz ES, Schonberger LB. Guillain-Barre syndrome in the United States, 1979-1980 and 1980-1981. Lack of an association with influenza vaccination. JAMA 1982;248(6):698-700.
Keitel 1988a {published data only}
  • Keitel WA, Cate TR, Couch RB. Efficacy of sequential annual vaccination with inactivated influenza virus vaccine. American Journal of Epidemiology 1988;127(2):353-64.
Keitel 1988b {published data only}
  • Keitel WA, Cate TR, Couch RB. Efficacy of sequential annual vaccination with inactivated influenza virus vaccine. American Journal of Epidemiology 1988;127(2):353-64.
Keitel 1993a {published data only}
  • Keitel WA, Couch RB, Quarles JM, Cate TR, Baxter B, Maassab HF. Trivalent attenuated cold-adapted influenza virus vaccine: reduced viral shedding and serum antibody responses in susceptible adults. Journal of Infectious Diseases 1993;167(2):305-11.
Keitel 1993b {published data only}
  • Keitel WA, Couch RB, Quarles JM, Cate TR, Baxter B, Maassab HF. Trivalent attenuated cold-adapted influenza virus vaccine: reduced viral shedding and serum antibody responses in susceptible adults. Journal of Infectious Diseases 1993;167(2):305-11.
Keitel 1997a {published data only}
Keitel 1997b {published data only}
Keitel 1997c {published data only}
Langley 2005 {published data only}
  • Langley JM, Halperin SA, McNeil S, Smith B, Jones T, Burt D, et al. Safety and immunogenicity of a Proteosometrade mark-trivalent inactivated influenza vaccine, given nasally to healthy adults. Vaccine 2005;24(10):1601-8.
Lasky 1998 {published data only}
  • Lasky T, Terracciano GJ, Magder L, Koski CL, Ballesteros M, Nash D, et al. The Guillain-Barre syndrome and the 1992-1993 and 1993-1994 influenza vaccines. New England Journal of Medicine 1998;339(25):1797-802.
Lauteria 1974 {published data only}
  • Lauteria SF, Kantzler GB, High PC, Lee JD, Waldman RH. An attenuated influenza virus vaccine: Reactogenicity, transmissibility, immunogenicity, and protective efficacy. Journal of Infectious Diseases 1974;130(4):380-3.
Leibovitz 1971 {published data only}
  • Leibovitz A, Coultrip RL, Kilbourne ED, Legters LJ, Smith CD, Chin J, et al. Correlated studies of a recombinant influenza-virus vaccine. IV. Protection against naturally occurring influenza in military trainees. Journal of Infectious Diseases 1971;124(5):481-7.
Mastrangelo 2000 {published data only}
  • Mastrangelo G, Rossi CR, Pfahlberg A, Marzia V, Barba A, Baldo M, et al. Is there a relationship between influenza vaccinations and risk of melanoma? A population-based case-control study. European Journal of Epidemiology 2000;16(9):777-82.
Mesa Duque 2001 {published data only}
  • Mesa-Duque SS, Moreno AP, Hurtado G, Arbelàaz Montoya MP. Effectiveness of an Influenza Vaccine in a working population in Colombia [Effectividad de una vacuna anti gripal en una poblaciòn laboral colombiana]. Pan American Journal of Public Health 2001;10(4):232-9.
Miller 1977 {published data only}
Mixéu 2002 {published data only}
  • Mixèu MA, Vespa GN, Forleo-Neto E, Toniolo-Neto J, Alves PM. Impact of influenza vaccination on civilian aircrew illness and absenteism. Aviation, Space, and Environmental Medicine 2002;73(9):876-80.
Mogabgab 1970a {published data only}
Mogabgab 1970b {published data only}
Monto 1982 {published data only}
Mutsch 2004 {published data only}
  • Mutsch M, Zhou W, Rhodes P, Bopp M, Chen RT, Linder T, et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. New England Jouranl of Medicine 2004;350(9):896-903.
Nichol 1995 {published data only}
Nichol 1999a {published data only}
  • Nichol KL, Mendelman PM, Mallon KP, Jackson LA, Gorse GJ, Belshe RB, et al. Effectiveness of live attenuated intranasal influenza virus vaccine in healthy working adults , a randomize controlled trial. JAMA 1999;282(2):137-44.
Payne 2006 {published data only}
  • Payne DC, Rose CE Jr, Kerrison J, Aranas A, Duderstadt S, McNeil MM. Anthrax vaccination and risk of optic neuritis in the United States military, 1998-2003. Archives of Neurology 2006;63(6):871-5.
Phyroenen 1981 {published data only}
Powers 1995a {published data only}
  • Powers DC, Smith GE, Anderson EL, et al. Influenza A virus vaccine containing purified recombinant H3 hemagglutinin are well tolerated and induce protective immune responses in healthy adults. Journal of Infectious Diseases 1995;171:1595-9.
Powers 1995b {published data only}
  • Powers DC, Smith GE, Anderson EL, et al. Influenza A virus vaccine containing purified recombinant H3 hemagglutinin are well tolerated and induce protective immune responses in healthy adults. Journal of Infectious Diseases 1995;171:1595-9.
Powers 1995c {published data only}
  • Powers DC, Smith GE, Anderson EL, et al. Influenza A virus vaccine containing purified recombinant H3 hemagglutinin are well tolerated and induce protective immune responses in healthy adults. Journal of Infectious Diseases 1995;171:1595-9.
Reeve 1982 {published data only}
Rocchi 1979a {published data only}
  • Rocchi G, Ragona G, Piga C, Pelosio A, Volpi A, Vella S, et al. Influenza vaccination with live-attenuated and inactivated virus-vaccines during an outbreak of disease. Journal of Hygiene 1979;83(3):383-90.
Rocchi 1979b {published data only}
  • Rocchi G, Ragona G, Piga C, Pelosio A, Volpi A, Vella S, et al. Influenza vaccination with live-attenuated and inactivated virus-vaccines during an outbreak of disease. Journal of Hygiene 1979;83(3):383-90.
Rytel 1977 {published data only}
  • Rytel MW, Jakson LJ, Niebojewski RA, et al. Field trial of live attenuated influenza A/B ("Alice"/R-75) vaccine. American Journal of Epidemiology 1977;105(1):49-55.
Saxen 1999 {published data only}
  • Saxen H, Virtanen M. Randomized, placebo-controlled double blind study on the efficacy of influenza immunization on absenteeism of health care workers. Pediatric Infectious Disease Journal 1999;18(9):779-83.
Scheifele 2003 {published data only}
  • Scheifele DW, Duval B, Russell ML, Warrington R, DeSerres G, Skowronski DM, et al. Ocular and respiratory symptoms attributable to inactivated split influenza vaccine: evidence from a controlled trial involving adults. Clinical Infectious Diseases 2003;36(7):850-7.
Shoenberger 1979 {published data only}
  • Schonberger LB, Bregman DJ, Sullivan-Bolyai JZ, Keenlyside RA, Ziegler DW, Retailliau HF, et al. Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976 - 1977. American Journal of Epidemiology 1979;110(2):105-23.
Siscovick 2000 {published data only}
  • Siscovick DS, Raghunathan TE, Lin D, Weinmann S, Arbogast P, Lemaitre RN, et al. Influenza vaccination and the risk of primary cardiac arrest. American Journal of Epidemiology 2000;152(7):674-7.
Spencer 1977 {published data only}
  • Spencer MJ, Cherry JD, Powell KR. Clinical trial with "R-75" strain live, attenuated, serum inhibitor-resistant intranasal influenza B vaccine. Journal of Clinical Microbiology 1977;5(6):584-7.
Sumarokow 1971 {published data only}
  • Sumarokow AA, Popov VF, Nefedova LA, et al. A study of live influenza vaccines in a controlled trial. Zhumal Mikrobiologii Epidemiologii Immunobiologii 1971;48(2):46-52.
Tannock 1984 {published data only}
  • Tannock GA, Bryce DA, Hensley MJ, et al. Responses to one or two doses of a deoxycholate subunit influenza vaccine in a primed population. Vaccine 1984;2:100-5.
Waldman 1969a {published data only}
Waldman 1969b {published data only}
Waldman 1969c {published data only}
Waldman 1969d {published data only}
Waldman 1972a {published data only}
Waldman 1972b {published data only}
Waldman 1972c {published data only}
Waldman 1972d {published data only}
Weingarten 1988 {published data only}
Zhilova 1986a {published data only}
  • Zhilova GP, Ignat'eva GS, Orlov VA, Malikova EV, Maksakova VL. Results of a study of the effectiveness of simultaneous immunization against influenza with live and inactivated vaccines (1980 - 1983). Voprosy Virusologii 1986;31(1):40-4.
Zhilova 1986b {published data only}
  • Zhilova GP, Ignat'eva GS, Orlov VA, Malikova EV, Maksakova VL. Results of a study of the effectiveness of simultaneous immunization against influenza with live and inactivated vaccines (1980 - 1983). Voprosy Virusologii 1986;31(1):40-4.

References to studies excluded from this review

  1. Top of page
  2. Abstract
  3. Background
  4. Objectives
  5. Methods
  6. Results
  7. Discussion
  8. Authors' conclusions
  9. Acknowledgements
  10. Data and analyses
  11. Appendices
  12. Feedback
  13. What's new
  14. History
  15. Contributions of authors
  16. Declarations of interest
  17. Sources of support
  18. Characteristics of studies
  19. References to studies included in this review
  20. References to studies excluded from this review
  21. Additional references
  22. References to other published versions of this review
Ambrosch 1976 {published data only}
  • Ambrosch F, Balluch H. Studies of the non-specific clinical effectiveness of influenza vaccination. Laryngologie, Rhinologie, Otologie Laryngologie, Rhinologie, Otologie 1976;55:57-61.
Aoki 1986 {published data only}
  • Aoki FY, Sitar DS, Milley EV, et al. Potential of influenza vaccine and amantadine to prevent influenza A illness in canadian forces personnel 1980-83. Military Medicine 1986;151(9):459-65.
Atmar 1995 {published data only}
  • Atmar RL, Keitel WA, Cate TR, Quarles JM, Couch RB. Comparison of trivalent cold-adapted recombinant (CR) influenza virus vaccine with monovalent CR vaccines in healthy unselected adults. Journal of Infectious Diseases 1995;172(1):253-7.
Ausseil 1999 {published data only}
Banzhoff 2001 {published data only}
Belshe 2001 {published data only}
  • Belshe RB, Gruber WC. Safety, efficacy and effectiveness of cold-adapted, live, attenuated, trivalent, intranasal influenza vaccine in adults and children. Philosophical transactions of the Royal Society of London 2001;356(1416):1947-51.
Benke 2004 {published data only}
Betts 1977b {published data only}
  • Betts RF, Douglas RG Jr. Comparative study of reactogenicity and immunogenicity of influenza A/New Jersey/8/76 (Hsw1N1) virus vaccines in normal volunteers. Journal of Infectious Diseases 1977;136(Suppl):443-9.
Beyer 1996 {published data only}
  • Beyer WEP, Palache AM, Kerstens R, Masurel N. Gender differences in local and systemic reactions to inactivated influenza vaccine, established by a meta-analysis of fourteen independent studies. European Journal of Clinical Microbiology & Infectious Diseases 1996;15(1):65-70.
Carlson 1979 {published data only}
  • Carlson AJ, Davidson WL, McLean AA, Vella PP, Weibel RE, Woodhour AF, et al. Pneumococcal vaccine: dose, revaccination, and coadministration with influenza vaccine. Proceedings of the Society for Experimental Biology and Medicine 1979;161(4):558-63.
Cate 1977 {published data only}
  • Cate TR, Couch RB, Kasel JA, Six HR. Clinical trials of monovalent influenza A/New Jersey/76 virus vaccines in adults: reactogenicity, antibody response, and antibody persistence. Journal of Infectious Diseases 1977;136(Suppl):450-5.
Chlibek 2002 {published data only}
  • Chlibek R, Beran J, Splino M. Effectiveness of influenza vaccination in healthy adults--a fourfold decrease in influenza morbidity during one influenza season. Epidemiologie, Mikrobiologie, Imunologie 2002;51(2):47-51.
Clover 1991 {published data only}
  • Clover RD, Crawford S, Glezen WP, et al. Comparison of heterotypic protection against influenza A/Taiwan/86 (H1N1) by attenuated and inactivated vaccines to A/Chile/83-like viruses. Journal of Infectious Diseases 1991;163:300-4.
Confavreux 2001 {published data only}
  • Confavreux C, Suissa S, Saddier P, Bourdes V, Vukusic S. Vaccinations and the risk of relapse in multiple sclerosis. Vaccines in Multiple Sclerosis Study Group. New England Journal of Medicine 2001;344(5):319-26.
Das Gupta 2002 {published data only}
Davies 1972 {published data only}
  • Davies JE, Howell RW, Meichen FW. A clinical trial of inhaled inactivated influenza vaccine. British Journal of Clinical Practice 1972;26(10):469-71.
Davies 1973 {published data only}
  • Davies JE, Howell RH, Meichen FW. A clinical trial of inhaled inactivated influenza vaccine. British Journal of General Practice 1970;27(6):219-21.
De Serres 2003a {published data only}
  • De Serres GI, Boulianne N, Duval B, Rochette L, Grenier JL, Roussel R, et al. Oculo-respiratory syndrome following influenza vaccination: evidence for occurrence with more than one influenza vaccine. Vaccine 2003;21(19-20):2346-53.
De Serres 2003b {published data only}
  • De Serres GI, Grenier JL, Toth E, Menard S, Roussel R, Tremblay M, et al. The clinical spectrum of the oculo-respiratory syndrome after influenza vaccination. Vaccine 2003;21(19-20):2354-61.
De Serres 2004 {published data only}
  • De Serres G, Skowronski DM, Guay M, Rochette L, Jacobsen K, Fuller T, et al. Recurrence risk of oculorespiratory syndrome after influenza vaccination: randomized controlled trial of previously affected persons. Archives of Internal Medicine 2004;164(20):2266-72.
Dolin 1977 {published data only}
  • Dolin R, Wise TG, Mazur MH, Tuazon CU, Ennis FA. Immunogenicity and reactogenicity of influenza A/New Jersey/76 virus vaccines in normal adults. Journal of Infectious Diseases 1977;136(Suppl):435-42.
Edmonson 1970 {published data only}
  • Edmonson KW, Graham SM, Warburton MF. A clinical trial of influenza vaccine in Canberra. Medical Journal of Australia 1970;4:6-13.
El'shina 1998 {published data only}
  • El'shina GA, Gorbunov MA, Shervarli VI, Lonskaia NI, Pavlova LI, Khaitov RM, et al. Evaluation of the effectiveness of influenza trivalent polymer subunit vaccine "Grippol". Zhumal Mikrobiologii Epidemiologii Immunobiologii 1998;3:40-3.
Finklea 1969 {published data only}
  • Finklea JF, Sandifer SH, Peck FB, et al. A clinical and serologic comparison of standard and purified bivalent inactivated influenza vaccines. Journal of Infectious Diseases 1969;120(6):708-12.
Foy 1981 {published data only}
  • Foy HM, Cooney MK, Allan ID, Frost F, Blumhagen JM, Fox JP. Influenza B virus vaccines in children and adults: adverse reactions, immune response, and observations in the field. Journal of Infectious Diseases 1981;143(5):700-6.
Frank 1981 {published data only}
Freestone 1976 {published data only}
  • Freestone DS. Clinical trials with intranasally administered WRL 105 strain live influenza vaccine in volunteers. Developments in Biological Standardization 1976;33:207-12.
Gerstoft 2001 {published data only}
  • Gerstoft J. Influenza vaccination of healthy adults. Ugeskrift for Laeger 2001;163(19):2615-7.
Greenbaum 2002 {published data only}
  • Greenbaum E, Furst A, Kiderman A, Stewart B, Levy R, Schlesinger M, et al. Mucosal [SIgA] and serum [IgG] immunologic responses in the community after a single intra-nasal immunization with a new inactivated trivalent influenza vaccine. Vaccine 2002;20(7-8):1232-9.
Gross 1999 {published data only}
  • Gross PA, Sperber SJ, Donabedian A, Dran S, Morchel G, Cataruozolo P, et al. Paradoxical response to a novel influenza virus vaccine strain: the effect of prior immunization. Vaccine 1999;17(18):2284-9.
Grotto 1998 {published data only}
Gruber 1994 {published data only}
  • Gruber WC, Campbell PW, Thompson MJ, et al. Comparison of live attenuated and inactivated influenza vaccines in Cystic Fibrosis Patients and their families: results of a 3-years study. Journal of Infectious Diseases 1994;169:241-7.
Haber 2004 {published data only}
Haigh 1973 {published data only}
Halperin 2002 {published data only}
  • Halperin SA, Smith B, Mabrouk T, Germain M, Trepanier P, Hassell T, et al. Safety and immunogenicity of a trivalent, inactivated, mammalian cell culture-derived influenza vaccine in healthy adults, seniors, and children. Vaccine 2002;20(7-8):1240-7.
Hobson 1970 {published data only}
  • Hobson D, Baker FA, Chivers CP, et al. A comparison of monovalent Hong Kong influenza virus vaccine with vaccines containing only pre-1968 Asian strains in adult volunteers. Journal of Hygiene 1970;68:369-78.
Hobson 1973 {published data only}
Hoskins 1973 {published data only}
  • Hoskins TW, Davies JR, Allchin A, et al. Controlled trial of inactivated influenza vaccine containing the A/Hong Kong strain during an outbreak of influenza due to the A/England/42/72 strain. Lancet 1973;July 21:116-20.
Hoskins 1976a {published data only}
  • Hoskins TW, Davies JR, Smith AJ, et al. Influenza at Christ's Hospital: March, 1974. Lancet 1976;January 17:105-8.
Hoskins 1976b {published data only}
  • Hoskins TW, Davies JR, Smith AJ, et al. Influenza at Christ's Hospital: March, 1974. Lancet 1976;January 17:105-8.
Hoskins 1979 {published data only}
  • Hoskins TW, Davies JR, Smith AJ, et al. Assessment of inactivated influenza A vaccine after three outbreaks of influenza A at Christ's Hospital. Lancet 1979;January 6:33-5.
Howell 1967 {published data only}
Hurwitz 1983 {published data only}
Jianping 1999 {published data only}
  • Jianping H, Xin F, Changshun L, Bo Z, Linxiu G, Wei X, et al. Assessment of effectiveness of Vaxigrip. Vaccine 1999;17(Suppl 1):57-8.
Keitel 2001 {published data only}
  • Keitel WA, Cate TR, Nino D, Huggins LL, Six HR, Quarles JM, et al. Immunization against influenza: comparison of various topical and parenteral regimens containing inactivated and/or live attenuated vaccines in healthy adults. Journal of Infectious Diseases 2001;183(2):329-32.
Kiderman 2001 {published data only}
  • Kiderman A, Furst A, Stewart B, Greenbaum E, Morag A, Zakay-Rones Z. A double-blind trial of a new inactivated, trivalent, intra-nasal anti-influenza vaccine in general practice: relationship between immunogenicity and respiratory morbidity over the winter of 1997-98. Journal of Clinical Virology 2001;20(3):155-61.
Kunz 1977 {published data only}
  • Kunz C, Hofmann H, Bachmayer H, Liehl E, Moritz AJ. Clinical trials with a new influenza subunit vaccine in adults and children. Developments in Biological Standardization 1977;39:297-302.
Langley 2004 {published data only}
Liem 1973 {published data only}
Mackenzie 1975 {published data only}
Mair 1974 {published data only}
Maynard 1968 {published data only}
  • Maynard JE, Dull HB, Hanson ML, et al. Evaluation of monovalent and polyvalent influenza vaccines during an epidemic of type A2 and B influenza. American Journal of Epidemiology 1968;87(1):148-57.
McCarthy 2004 {published data only}
Mendelman 2001 {published data only}
  • Mendelman PM, Cordova J, Cho I. Safety, efficacy and effectiveness of the influenza virus vaccine, trivalent, types A and B, live, cold-adapted (CAIV-T) in healthy children and healthy adults. Vaccine 2001;19(17-19):2221-6.
Merelli 2000 {published data only}
  • Merelli E, Casoni F. Prognostic factors in multiple sclerosis: role of intercurrent infections and vaccinations against influenza and hepatitis B. Neurological Sciences 2000;21(4 Suppl 2):853-6.
Meyers 2003a {published data only}
  • Meyers DG. Could influenza vaccination prevent myocardial infarction, stroke and sudden cardiac death?. American Journal of Cardiovascular Drugs 2003;3(4):241-4.
Meyers 2003b {published data only}
  • Meyers DG. Myocardial infarction, stroke, and sudden cardiac death may be prevented by influenza vaccination. Current Atherosclerosis Reports 2003;5(2):146-9.
Monto 2000 {published data only}
Morris 1975 {published data only}
Mostow 1977 {published data only}
  • Mostow SR, Eichkoff TC, Chelgren GA, et al. Studies of inactivated influenza virus vaccines in hospital employees: reactogenicity and absenteeism. Journal of Infectious Diseases 1977;136:533-8.
Muennig 2001 {published data only}
Nichol 1996 {published data only}
Nichol 1999b {published data only}
Nichol 2001 {published data only}
Nichol 2003 {published data only}
  • Nichol KL, Mallon KP, Mendelman PM. Cost benefit of influenza vaccination in healthy, working adults: an economic analysis based on the results of a clinical trial of trivalent live attenuated influenza virus vaccine. Vaccine 2003;21(17-18):2207-17.
Nichol 2004 {published data only}
  • Nichol KL, Mendelman P. Influence of clinical case definitions with differing levels of sensitivity and specificity on estimates of the relative and absolute health benefits of influenza vaccination among healthy working adults and implications for economic analyses. Virus Research 2004;103(1-2):3-8.
Pyhala 2001 {published data only}
  • Pyhala R, Haanpaa M, Kleemola M, Tervahauta R, Visakorpi R, Kinnunen L. Acceptable protective efficacy of influenza vaccination in young military conscripts under circumstances of incomplete antigenic and genetic match. Vaccine 2001;19(23-24):3253-60.
Rimmelzwaan 2000 {published data only}
  • Rimmelzwaan GF, Nieuwkoop N, Brandenburg A, Sutter G, Beyer WE, Maher D, et al. A randomized, double blind study in young healthy adults comparing cell mediated and humoral immune responses induced by influenza ISCOM vaccines and conventional vaccines. Vaccine 2000;19(9-10):1180-7.
Rocchi 1979c {published data only}
  • Rocchi G, Carlizza L, Andreoni M, Ragona G, Piga C, Pelosio A, et al. Protection from natural infection after live influenza virus immunization in an open population. Journal of Hygiene 1979;82(2):231-6.
Ruben 1972 {published data only}
Ruben 1973 {published data only}
Safranek 1991 {published data only}
  • Safranek TJ, Lawrence DN, Kurland LT, Culver DH, Wiederholt WC, Hayner NS, et al. Reassessment of the association between Guillain-Barre syndrome and receipt of swine influenza vaccine in 1976-1977: results of a two-state study. Expert Neurology Group. American Journal of Epidemiology 1991;133(9):940-51.
Sarateanu 1980 {published data only}
  • Sarateanu DE, Ehrengut W, Pressler K, Peukert M, Schenk KD. Serological response to whole, split and subunit influenza vaccines of persons with and without immunological experience towards influenza A/U.S.S.R. 90/77 virus. Comparative Immunology, Microbiology and Infectious Diseases 1980;3(1-2):225-36.
Schonberger 1981 {published data only}
Schwartz 1996 {published data only}
Skowronski 2002 {published data only}
  • Skowronski DM, Strauss B, Kendall P, Duval B, De Serres G. Low risk of recurrence of oculorespiratory syndrome following influenza revaccination. CMAJ 2002;167(8):853-8.
Skowronski 2003 {published data only}
  • Skowronski DM, De Serres G, Scheifele D, Russell ML, Warrington R, Davies HD, et al. Randomized, double-blind, placebo-controlled trial to assess the rate of recurrence of oculorespiratory syndrome following influenza vaccination among persons previously affected. Clinical Infectious Diseases 2003;37(8):1059-66.
Smith 1977a {published data only}
Smith 1977b {published data only}
  • Smith CD, Leighton HA, Shiromoto RS. Antigenicity and reactivity of influenza A/New Jersey/8/76 virus vaccines in military volunteers at Fort Ord, California. Journal of Infectious Diseases 1977;136(Suppl):460-5.
Spencer 1975 {published data only}
  • Spencer MJ, Cherry JD, Powell KR, et al. Clinical trials with Alice strain, live attenuated, serum inhibitor-resistant intranasal influenza A vaccine. Journal of Infectious Diseases 1975;132(4):415-20.
Spencer 1979 {published data only}
  • Spencer MJ, Cherry JD, Powell KR, et al. A clinical trial with Alice/R-75 strain, live attenuated serum inhibitor-resistant intranasal bivalent influenza A/B vaccine. Medical Microbiology and Immunology 1979;167:1-9.
Taylor 1969 {published data only}
  • Taylor PJ, Miller CL, Pollock TM, et al. Antibody response and reactions to aqueous influenza vaccine, simple emulsion vaccine and multiple emulsion vaccine. A report to the Medical Research Council Committee on influenza and other respiratory virus vaccines. Journal of Hygiene 1969;67:485-90.
Treanor 2001 {published data only}
  • Treanor JJ, Wilkinson BE, Masseoud F, Hu-Primmer J, Battaglia R, O'Brien D, et al. Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine 2001;19(13-14):1732-7.
Treanor 2002 {published data only}
  • Treanor J, Keitel W, Belshe R, Campbell J, Schiff G, Zangwill K, et al. Evaluation of a single dose of half strength inactivated influenza vaccine in healthy adults. Vaccine 2002;20(7-8):1099-105.
Tyrrell 1970 {published data only}
  • Tyrrell DA, Buckland R, Rubenstein D, Sharpe DM. Vaccination against Hong Kong influenza in Britain, 1968-9. A report to the Medical Research Council Committee on Influenza and other Respiratory Virus Vaccines. Journal of Hygiene 1970 Sep;68(3):359-68.
Warshauer 1976 {published data only}
  • Warshauer DM, Minor TE, Inhorn SL, et al. Use of an inhibitor-resistant live attenuated influenza vaccine in normal and asthmatic adults. 14th Congress of the International Association of Biological Standardization, Douglas, Isle of Man 1975. Developments in Biological Standardization 1975;33:184-90.
Wilde 1999 {published data only}
Williams 1973 {published data only}
Wood 1999 {published data only}
  • Wood SC, Alexseiv A, Nguyen VH. Effectiveness and economical impact of vaccination against influenza among a working population in Moscow. Vaccine 1999;17(Suppl 3):81-7.
Wood 2000 {published data only}

Additional references

  1. Top of page
  2. Abstract
  3. Background
  4. Objectives
  5. Methods
  6. Results
  7. Discussion
  8. Authors' conclusions
  9. Acknowledgements
  10. Data and analyses
  11. Appendices
  12. Feedback
  13. What's new
  14. History
  15. Contributions of authors
  16. Declarations of interest
  17. Sources of support
  18. Characteristics of studies
  19. References to studies included in this review
  20. References to studies excluded from this review
  21. Additional references
  22. References to other published versions of this review
ACIP 2006
  • Centers for Disease Control and Prevention. Prevention and control of influenza: Recommendations of the Advisory Committee on Immunization Practices (ACIP). Recommendations and Reports : Morbidity and mortality weekly report 2006;55:1-41.
DerSimonian 1986
Higgins 2002
Higgins 2003
Higgins 2005
  • Higgins JPT, Green S, editors. Analysing and presenting results. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]; Section 8. The Cochrane Library. Vol. Issue 3, Chichester, UK: John Wiley & Sons, Ltd, 2005.
Jefferson 2004
Wells 2004
  • Wells GA, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http://www.ohri.ca/programs/clinical_epidemiology/oxford web.ppt 2004.
Wiselka 1994

References to other published versions of this review

  1. Top of page
  2. Abstract
  3. Background
  4. Objectives
  5. Methods
  6. Results
  7. Discussion
  8. Authors' conclusions
  9. Acknowledgements
  10. Data and analyses
  11. Appendices
  12. Feedback
  13. What's new
  14. History
  15. Contributions of authors
  16. Declarations of interest
  17. Sources of support
  18. Characteristics of studies
  19. References to studies included in this review
  20. References to studies excluded from this review
  21. Additional references
  22. References to other published versions of this review
Demicheli 1999
Demicheli 2001
  • Demicheli V, Rivetti D, Deeks JJ, Jefferson TO. Vaccines for preventing influenza in healthy adults. Cochrane Database of Systematic Reviews 2001, Issue 4. [DOI: 10.1002/14651858.CD001269.pub3]
Demicheli 2004
  • Demicheli V, Rivetti D, Deeks JJ, Jefferson TO. Vaccines for preventing influenza in healthy adults. Cochrane Database of Systematic Reviews 2004, Issue 3. [DOI: 10.1002/14651858.CD001269.pub3]